Funding for this research was provided by:
National Cancer Institute (R01CA157303)
Georgia Research Alliance (GRA Eminent Scholar Chair in Tumor Immunology)
Article History
Received: 24 February 2017
Accepted: 25 April 2017
First Online: 8 May 2017
Compliance with ethical standards
:
: Esteban Celis has filed patent applications based on the use of synthetic peptides and poly-IC combinatorial vaccines. The rights of the patent applications have been transferred to the Moffitt Cancer Center (Tampa, FL). All the other authors do not have any conflict of interest.